デフォルト表紙
市場調査レポート
商品コード
1377981

K-321の新興薬剤に関する洞察と市場予測:2032年

K-321 Emerging Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
K-321の新興薬剤に関する洞察と市場予測:2032年
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

興和新薬が開発中のK-321(リパスジル)は、従来の房水流出を増加させることにより眼圧を低下させるRho-キナーゼ阻害薬です。Rho-関連タンパク質キナーゼ(ROCK)は、眼球を含むいくつかの組織において細胞の形や動きを制御するタンパク質です。

ROCK阻害剤は、従来の流出組織であるトラベキュラーメッシュワーク(TM)とシュレム管(SC)の細胞内アクチンを解重合させることによって眼圧を低下させます。さらに、ROCK阻害剤はTM細胞による細胞外マトリックス産生を抑制するため、眼圧下降の代替薬となる可能性があります。

当レポートでは、主要7ヶ国におけるK-321市場について調査し、市場の概要とともに、2025年~2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 FECDに対するK-321の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • その他の開発活動
  • 製品概要

第3章 競合情勢(上市済み治療法)

第4章 競合情勢(後期段階の新興治療法)

第5章 K-321市場評価

  • FECDに対するK-321の市場展望
  • 主要7ヶ国市場分析
    • 主要7ヶ国におけるFECDに対するK-321の市場規模
  • 国別市場分析
    • 米国
    • ドイツ
    • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: K-321, Clinical Trial Description, 2023
  • Table 2: K-321, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: K-321 Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: K-321 Market Size in the US, in USD million (2019-2032)
  • Table 7: K-321 Market Size in Germany, in USD million (2019-2032)
  • Table 8: K-321 Market Size in France, in USD million (2019-2032)
  • Table 9: K-321 Market Size in Italy, in USD million (2019-2032)
  • Table 10: K-321 Market Size in Spain, in USD million (2019-2032)
  • Table 11: K-321 Market Size in the UK, in USD million (2019-2032)
  • Table 12: K-321 Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: K-321 Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: K-321 Market Size in the United States, USD million (2019-2032)
  • Figure 3: K-321 Market Size in Germany, USD million (2019-2032)
  • Figure 4: K-321 Market Size in France, USD million (2019-2032)
  • Figure 5: K-321 Market Size in Italy, USD million (2019-2032)
  • Figure 6: K-321 Market Size in Spain, USD million (2019-2032)
  • Figure 7: K-321 Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: K-321 Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1121

“"K-321 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about K-321 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets. A detailed picture of the K-321 for FECD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the K-321 for FECD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the K-321 market forecast analysis for FECD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FECD.

Drug Summary:

K-321 (Ripasudil), being developed by Kowa Pharmaceuticals, is a rho-kinase inhibitor that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Rho-associated protein kinase (ROCK) is a protein that regulates the shape and movement of cells in several tissues, including the eye.

ROCK inhibitors lower IOP by depolymerizing intracellular actin in the conventional outflow tissues: the Trabecular Meshwork (TM) and Schlemm's canal (SC). Furthermore, ROCK inhibitors suppress extracellular matrix production by TM cells, representing a potential alternative to lowering IOP.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the K-321 description, mechanism of action, dosage and administration, research and development activities in Fuchs Endothelial Corneal Dystrophy (FECD).
  • Elaborated details on K-321 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the K-321 research and development activities in FECD across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around K-321.
  • The report contains forecasted sales of K-321 for FECD till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for FECD.
  • The report also features the SWOT analysis with analyst views for K-321 in FECD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

K-321 Analytical Perspective by DelveInsight

  • In-depth K-321 Market Assessment

This report provides a detailed market assessment of K-321 for Fuchs Endothelial Corneal Dystrophy (FECD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

  • K-321 Clinical Assessment

The report provides the clinical trials information of K-321 for FECD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for Fuchs Endothelial Corneal Dystrophy (FECD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence K-321 dominance.
  • Other emerging products for FECD are expected to give tough market competition to K-321 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of K-321 in FECD.
  • Our in-depth analysis of the forecasted sales data of K-321 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the K-321 in FECD.

Key Questions

  • What is the product type, route of administration and mechanism of action of K-321?
  • What is the clinical trial status of the study related to K-321 in Fuchs Endothelial Corneal Dystrophy (FECD) and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the K-321 development?
  • What are the key designations that have been granted to K-321 for FECD?
  • What is the forecasted market scenario of K-321 for FECD?
  • What are the forecasted sales of K-321 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to K-321 for FECD?
  • Which are the late-stage emerging therapies under development for the treatment of FECD?

Table of Contents

1. Report Introduction

2. K-321 Overview in FECD

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. K-321 Market Assessment

  • 5.1. Market Outlook of K-321 in FECD
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of K-321 in the 7MM for FECD
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of K-321 in the United States for FECD
    • 5.3.2. Market Size of K-321 in Germany for FECD
    • 5.3.3. Market Size of K-321 in France for FECD
    • 5.3.4. Market Size of K-321 in Italy for FECD
    • 5.3.5. Market Size of K-321 in Spain for FECD
    • 5.3.6. Market Size of K-321 in the United Kingdom for FECD
    • 5.3.7. Market Size of K-321 in Japan for FECD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options